Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
15-valent recombinant human papillomavirus vaccine
- Development stage
- Phase 1
- Lead developer
- Shanghai Bovax Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**15-valent recombinant human papillomavirus vaccine** is an investigational prophylactic HPV vaccine developed by Shanghai Bovax Biotechnology and Chongqing Bovax Biopharmaceutical. It consists of recombinant virus-like particles formed from the HPV major capsid protein L1 for HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, expressed in *Hansenula polymorpha* and adsorbed to an aluminium adjuvant. The noninfectious L1 virus-like particles are intended to induce type-specific neutralizing antibodies that prevent infection with included HPV types and thereby prevent HPV-associated genital warts, precancerous lesions, and cancers. The program is in Phase 2 clinical development in healthy Chinese participants aged 9–45 years. ([bovaxbio.com](https://www.bovaxbio.com/en/sys-pd/4.html))
- Other names
- 15-valent HPV vaccinerecombinant 15-valent human papillomavirus vaccinerecombinant15-valent human papillomavirus vaccinerecombinant-15-valent human papillomavirus vaccine
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)HPV11 L1HPV16 (Human papillomavirus type 16)Human papillomavirus type 18 major capsid protein L1HPV31 L1Human papillomavirus type 35 major capsid protein L1Human papillomavirus type 39 major capsid protein L1HPV45 L1Human papillomavirus type 51 major capsid protein L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)Human papillomavirus type 56 major capsid protein L1HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)Human papillomavirus type 59 major capsid protein L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)Human papillomavirus type 68 major capsid protein L1
Beyond the preview
Go deeper on 15-valent recombinant human papillomavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 15-valent recombinant human papillomavirus vaccine.